Lasting shift in the gut microbiota in patients with acute myeloid leukemia

Armin Rashidi, Maryam Ebadi, Tauseef Ur Rehman, Heba Elhusseini, Hossam Fathi Halaweish, Thomas J Kaiser-Powers, Shernan G. Holtan, Alexander Khoruts, Daniel J. Weisdorf, Christopher Staley

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Previous studies have shown that the gut microbiota of patients with acute myeloid leukemia (AML) is disrupted during induction chemotherapy; however, the durability of microbiota changes is unknown. This is an important knowledge gap, because reduced microbiota diversity at the time of stem cell transplantation weeks to months after the initial chemotherapy has been associated with higher mortality after transplantation. By sequencing the gut microbiota in 410 longitudinal stool samples from 52 patients with AML, we found that, during inpatient chemotherapy, the gut microbiota is stressed beyond its ability to recover its original state. Despite major reductions in antibiotic pressure and other disturbances to the microbiota after hospital discharge, the trajectory of microbiota recovery yields new communities that are highly dissimilar to baseline. This lasting shift in the gut microbiota is relevant for subsequent phases of curative therapy and is a potential target for novel microbiota protective/restorative interventions. This trial was registered at as #NCT03316456.

Original languageEnglish (US)
Pages (from-to)3451-3457
Number of pages7
JournalBlood Advances
Issue number11
StatePublished - Jun 14 2022

Bibliographical note

Publisher Copyright:
© 2022 by The American Society of Hematology.


Dive into the research topics of 'Lasting shift in the gut microbiota in patients with acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this